GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » YoY Rev. per Sh. Growth

GNCAQ (Genocea Biosciences) YoY Rev. per Sh. Growth : 0.00% (As of Mar. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Genocea Biosciences's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2022 was 0.00%.

Genocea Biosciences's Revenue per Share for the three months ended in Mar. 2022 was $0.00.


Genocea Biosciences YoY Rev. per Sh. Growth Historical Data

The historical data trend for Genocea Biosciences's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences YoY Rev. per Sh. Growth Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100.00 - - - -17.24

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -100.00 242.86 - -

Genocea Biosciences YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Genocea Biosciences's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2021 )
=(Revenue per Share (A: Dec. 2021 )-Revenue per Share (A: Dec. 2020 ))/ | Revenue per Share (A: Dec. 2020 ) |
=(0.024-0.029)/ | 0.029 |
=-17.24 %

Genocea Biosciences's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2022 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2022 )
=(Revenue per Share (Q: Mar. 2022 )-Revenue per Share (Q: Mar. 2021 )) / | Revenue per Share (Q: Mar. 2021 )) |
=(0.004-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
Executives
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber director 2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell 10 percent owner
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner officer: VP of Research C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815

Genocea Biosciences Headlines

From GuruFocus

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 05-24-2022

Q4 2019 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-03-2022

Q4 2018 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2021 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Biosciences, Inc. - Special Call Transcript

By GuruFocus Research 02-13-2024

Q1 2020 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024